News

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 program must address to bring an oral AMD treatment to patients without options.

Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.

Ultra-widefield pediatric retinal scans plus adaptable AI reveal hidden eye issues during routine visits, enabling comfortable, scalable screening and earlier specialist referrals.

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory signaling.

Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a critical gap for patients with advanced inherited retinal degeneration who have limited treatment options.

Jay Chhablani, MD, a retina specialist from UPMC Vision Institute and director of the Choroidal Analysis and Research Lab at the University of Pittsburgh, discussed recent advancements in choroidal imaging.

Uveitis expert Nisha Acharya, recipient of ARVO’s Mildred Weisenfeld Award, discusses how clinical trials and big data are reshaping treatment, vaccination, and vision outcomes.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Paul Nderitu discusses Global RETFound, a diverse, worldwide retinal AI model that outperforms existing tools and sets a new standard for equitable, open-access medical AI.

NYU researchers discuss using CellChek C widefield specular microscopy to visualize and quantify corneal nerves in dry eye disease, revealing reduced nerve fiber length and inferior whorl changes and offering a practical alternative to in vivo confocal imaging.

At ARVO Michael Siatkowski, MD, and Jody Summers, PhD, stopped to discuss the rising rates of myopia in children and if anti-inflammatory drugs could play a role in slowing progression.

Single-shot optogenetic injection restores light sensitivity in advanced retinitis pigmentosa, delivering sustained vision gains for years with strong safety, expanding hope beyond gene-specific therapy.

At ARVO 2026, Michael Ip, MD, presented findings from a large-scale analysis of OCT biomarkers in patients with diabetic macular edema (DME), leveraging the robust DRCR Retina Network Protocol T dataset.

Aaron Lee, MD, and Cecilia Lee, MD, co-recipients of this year's Cogan Award at ARVO, reflect on what the award lecture means to them and their careers.

Learn how IBD affects gut and beyond—risk factors, gender differences, eye complications, and treatment options to manage flares and protect vision.

Dimitra Skondra, MD, PhD, discussed her talk on how the diet and gut microbiome can affect the development of age-related macular degeneration.

2026 marks 50 years of play.

Phase 3 data show subcutaneous elegrobart quickly reduces proptosis and diplopia in chronic thyroid eye disease, with convenient at-home dosing.

Oral QA102 shows imaging signals slowing drusen and GA progression in intermediate dry AMD at ARVO 2026, despite missing its primary end point.

Research suggests that one drop of atropine is all it takes for beneficial effects.

Data presented at ARVO 2026 show that high-dose gene therapy boosts central retinal sensitivity in X-linked retinitis pigmentosa, with the phase 3 VISTA study fully enrolled.

AI-assisted screening in glaucoma clinics flags patient distress early, improving adherence and outcomes without adding staff burden.

Phase 2 and phase 3 results in diabetic macular edema and uveitic macular edema support intravitreal anti–IL-6 therapy

Interim 6-month results from Part B of the LIGHTHOUSE trial show structural and functional improvements consistent with earlier cohorts; pivotal Phase 3 enrollment now underway with BLA filing targeted for 2028.

Ariel Ong, a fellow from University College London, discussed her ARVO poster, looking at her work on developing a scalable pipeline for data extraction from ophthalmic clinical letters and what significance that could have in managing patients.

Several presentations at ARVO 2026 show the field advancing on two fronts: extending how long therapies last and broadening what they target.